V1RH9 Inhibitors
V1RH9 inhibitors belong to a specialized class of chemical compounds designed to interact with a specific type of biological target known as V1RH9. The chemical structure of these inhibitors is tailored to bind selectively to the V1RH9 site with high affinity, which results in the modulation of its activity. The design of these molecules is rooted in the principles of medicinal chemistry and structural biology, where the three-dimensional architecture of the V1RH9 site is studied in detail to understand the key interaction points that are crucial for binding. The inhibitors are then crafted using a combination of organic synthesis, combinatorial chemistry, and computer-aided drug design techniques, which allows for the precise manipulation of their chemical properties to optimize their interaction with the V1RH9 site.
The development of V1RH9 inhibitors is a complex process that involves iterative cycles of design, synthesis, and testing to refine their selectivity and binding characteristics. Advanced analytical methods, such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and mass spectrometry, are employed to elucidate the structure of the inhibitors and their conformational dynamics upon binding to the V1RH9 site. The interaction between V1RH9 inhibitors and their target is also studied through various biochemical and biophysical assays, which provide insights into the binding kinetics and the nature of the inhibitory action exerted by these compounds. This level of understanding is critical for the development of highly specific inhibitors that can effectively interact with the V1RH9 site without affecting similar sites in the biological system, thereby ensuring a high degree of specificity in their action.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that blocks the epidermal growth factor receptor (EGFR) tyrosine kinase, which is upstream of several signaling pathways including PI3K-AKT. Inhibition of this pathway would decrease AKT activation and subsequently lead to reduced phosphorylation and activity of V1RH9, which is dependent on PI3K-AKT signaling for full activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). By inhibiting PI3K, it prevents the formation of PIP3 and the subsequent activation of AKT, resulting in decreased phosphorylation and activity of V1RH9, which operates downstream of AKT. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K. Similar to wortmannin, it prevents AKT activation by inhibiting the production of PIP3, leading to a decrease in the phosphorylation and functional activity of V1RH9. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that, by inhibiting the mTORC1 complex, leads to reduced protein synthesis and cell proliferation. As V1RH9 activity is modulated by mTORC1 signaling, inhibition by rapamycin would lead to its functional suppression. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases can phosphorylate and activate several downstream proteins, including those in the pathway of V1RH9. Inhibition of Src kinases would therefore diminish V1RH9 activation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. It prevents the activation of downstream signaling proteins that contribute to the phosphorylation state and therefore the activity of V1RH9. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor which blocks the activation of MAPK/ERK kinase. As the MAPK/ERK pathway can lead to the activation of proteins like V1RH9, PD98059 would indirectly inhibit its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that specifically inhibits MEK1 and MEK2, preventing the activation of the ERK pathway. Since V1RH9 is a downstream effector in this pathway, U0126 would result in reduced activity of V1RH9. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which blocks the activation of p38 MAP kinase. As p38 MAPK is involved in the stress response and may modulate the activity of V1RH9, its inhibition would lead to decreased V1RH9 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of a signaling pathway that can activate proteins such as V1RH9. By inhibiting JNK, SP600125 indirectly leads to reduced V1RH9 activity. | ||||||